130 related articles for article (PubMed ID: 30470264)
1. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
[TBL] [Abstract][Full Text] [Related]
2. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
Rodriguez FJ; Vizcaino MA; Lin MT
J Mol Diagn; 2016 Sep; 18(5):620-634. PubMed ID: 27444975
[TBL] [Abstract][Full Text] [Related]
4. Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.
Olar A; Sulman EP
Semin Radiat Oncol; 2015 Jul; 25(3):155-63. PubMed ID: 26050585
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.
Lorenz J; Rothhammer-Hampl T; Zoubaa S; Bumes E; Pukrop T; Kölbl O; Corbacioglu S; Schmidt NO; Proescholdt M; Hau P; Riemenschneider MJ
Acta Neuropathol Commun; 2020 Aug; 8(1):124. PubMed ID: 32758285
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
[TBL] [Abstract][Full Text] [Related]
8. Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas.
Garcia MA; Solomon DA; Haas-Kogan DA
Future Oncol; 2016 Jun; 12(12):1493-506. PubMed ID: 27072750
[TBL] [Abstract][Full Text] [Related]
9. STING is significantly increased in high-grade glioma with high risk of recurrence.
Zhong M; Long M; Han C; Ji S; Yang Q
Oncoimmunology; 2024; 13(1):2327682. PubMed ID: 38516268
[TBL] [Abstract][Full Text] [Related]
10. Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.
Deans ZC; Costa JL; Cree I; Dequeker E; Edsjö A; Henderson S; Hummel M; Ligtenberg MJ; Loddo M; Machado JC; Marchetti A; Marquis K; Mason J; Normanno N; Rouleau E; Schuuring E; Snelson KM; Thunnissen E; Tops B; Williams G; van Krieken H; Hall JA;
Virchows Arch; 2017 Jan; 470(1):5-20. PubMed ID: 27678269
[TBL] [Abstract][Full Text] [Related]
11. System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management.
Kang W; Kadri S; Puranik R; Wurst MN; Patil SA; Mujacic I; Benhamed S; Niu N; Zhen CJ; Ameti B; Long BC; Galbo F; Montes D; Iracheta C; Gamboa VL; Lopez D; Yourshaw M; Lawrence CA; Aisner DL; Fitzpatrick C; McNerney ME; Wang YL; Andrade J; Volchenboum SL; Furtado LV; Ritterhouse LL; Segal JP
J Mol Diagn; 2018 Jul; 20(4):522-532. PubMed ID: 29698836
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Comito F; Melotti B; Marchese PV; Dika E; Venturi F; Corti B; Ciccimarra G; Ciceu CA; Tallini G; de Biase D
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667446
[TBL] [Abstract][Full Text] [Related]
13. Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.
Tan DS; Tan DS; Tan IBH; Yan B; Choo SP; Chng WJ; Hwang WYK
Asia Pac J Clin Oncol; 2020 Aug; 16(4):222-231. PubMed ID: 32301274
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.
Ji MS; Eldred BSC; Liu R; Pianka ST; Molaie D; Kevan B; Pan S; Lai TJ; Nguyen NT; Chow FE; Yong WH; Cox CD; Reeh DN; Li T; Liau LM; Nghiemphu PL; Cloughesy TF; Li G; Lai A
Neurooncol Adv; 2020; 2(1):vdaa009. PubMed ID: 32118206
[TBL] [Abstract][Full Text] [Related]
15. Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma.
Kobayashi A; Kitagawa Y; Nasser A; Wakimoto H; Yamada K; Tanaka S
Cells; 2024 Mar; 13(5):. PubMed ID: 38474421
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing: clinical applications in solid tumours.
Müllauer L
Memo; 2017; 10(4):244-247. PubMed ID: 29250205
[TBL] [Abstract][Full Text] [Related]
17. Classifying glioma via liquid biopsy--progress towards an unmet clinical need.
Abdullah KG
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38652677
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
19. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
[TBL] [Abstract][Full Text] [Related]
20. On high-risk, low-grade glioma: What distinguishes high from low?
Geurts M; van den Bent MJ
Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
